Monday, January 22, 2018

Juno Therapeutics Acquired For $9 Billion By Celgene

Seattle-based Juno Therapeutics, which develops cancer treatment drugs, has agreed to be acquired by New Jersey-based Celgene, the two companies announced this morning, in a deal worth approximately $9 billion. According to the two, Celgene will pay $87 per share in cash for Juno. Juno is a developer of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics, used to treat lymphoma patients. The deal had been rumored to be in the works last week.